Abstract
Cancer of the male breast is a very rare disease. It accounts for approximately 1% of all breast cancers and 0.2%–1% of all male cancers, without correlation to religion, geography, race, or occupation. Breast carcinoma in men is generally diagnosed at a more advanced stage and in older age groups (predominantly seventh decade) than breast cancer in women. Compared to women with similar prognostic variables, however, the general pattern of survival rates seems to be similar in both sexes [1,3, 10,18, 28].
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Adami H-O, Holmberg L, Malker B, Ries L (1985) Long-term survival in 406 males with breast cancer. Br J Cancer 52: 99–103
Becher R, Hoffken K, Pape H, Schmidt CG (1981) Tamoxifen treatment before orchiectomy in advanced breast cancer in men. N Engl J Med 305: 169–170
Crichlow RW (1974) Breast cancer in men. Semin Oncol 1: 145–152
Evans RM, Doelle GC, Lindner J, Bradley V, Rabin D (1984) A luteinizing hormone-releasing hormone agonist decreases biological activity and modifies chromatographic behavior of luteinizing hormone in man. J Clin Invest 73: 262–266
Everson RB, Lippman ME, Thompson EB, McGuire WL, Wittliff JL, De Sombre ER, Jensen EV, Singhakowinta A, Brooks SC Jr, Neifeld JP (1980) Clinical correlations of steroid receptors and male breast cancer. Cancer Res 40: 991–997
Farrow JH, Adair FE (1942) Effect of orchiectomy on skeletal metastases from cancer of the male breast. Science 95: 654
Harris AL, Dowsett M, Stuart-Harris R, Smith IE (1986) Role of aminoglutethimide in male breast cancer. Br J Cancer 54: 657–660
Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289 - 1294
Kahan A, Delrieu F, Amor B, Chiche R, Steg A (1984) Disease flare induced by D-Trp-LH-RH analogue in patients with metastatic prostatic cancer. Lancet I: 971–972
Kantarjian H, Yab H-Y, Hortobagyi G, Buzdar A, Blumenschein G (1983) Hormonal therapy for metastatic male breast cancer. Arch Intern Med 143: 237–240
Klijn JGM (1984) Long-term LH-RH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments. Med Oncol Tumor Pharmacother 1: 123–128
Kraybill WG, Kaufman R, Kinne D (1981) Treatment of advanced male breast cancer. Cancer 47: 2185–2189
Labrie F, Dupont A, Belanger A, Edmont J, Monfette G (1984) Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc Natl Acad Sci USA 81: 3861–3863
Labrie F, Dupont A, Belanger A, Lachance R, Giguere M (1985) Long-term treatment with luteinizing hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations. Br Med J 291: 369–370
Li MC, Janelli DE, Kelly EJ, Kashiwabara H, Kim RH (1970) Metastatic carcinoma of the male breast treated with bilateral adrenalectomy and chemotherapy. Cancer 25: 678–681
Lopez M (1985) Cyproterone acetate in the treatment of metastatic cancer of the male breast. Cancer 55: 2334–2336
Lopez M, di Lauro L, Papaldo P, Lazzaro B (1985) Chemotherapy in metastatic male breast cancer. Oncology 42: 205–209
Meyskens FL, Tormey DC, Neifeld JP (1976) Male breast cancer: a review. Cancer Treat Rev 3: 83–93
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Neifeld JP, Meyskens FL, Tormey DC, Javadpour N (1976) The role of orchiectomy in the management of advanced male breast cancer. Cancer 37: 992–995
Nirmul D, Pegoraro RJ, Jialal I, Naidoo C, Joubert SM (1983) The sex hormone profile of male patients with breast cancer. Br J Cancer 48: 423–427
Pannuti F, Martoni A, Busutti L, Gramellini M, Piaña E (1982) High-dose medroxyprogesterone acetate in advanced male breast cancer. Cancer Treat Rep 66: 1763–1765
Parmar H, Phillips RH, Lightman SL, Edwards L, Allen L, Schally AV (1985) Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet II: 1201–1205
Patel JK, Nemoto T, Dao TL (1984) Metastatic breast cancer in males. Assessment of endocrine therapy. Cancer 53: 1344–1346
Patterson JS, Battersby LA, Bach BK (1980) Use of tamoxifen in advanced male breast cancer. Cancer Treat Rep 64: 801–804
Presant CA, Soloway MS, Klioze SS, Kosola JW, Yakabow AL, Mendez RG, Kennedy PS, Wyres MR, Naessig VL, Ford KS (1985) Buserelin as primary therapy in advanced prostatic carcinoma. Cancer 56: 2416–2419
Redding TW, Schally AV (1981) Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 78: 6509–6512
Ribeiro G (1985) Male breast carcinoma - a review of 301 cases from the Christie Hospital and Holt Radium Institute, Manchester. Br J Cancer 51: 115–119
Schally AV, Redding TW, Comaru-Schally AM (1984) Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat Rep 68: 281–289
Scheulen ME, Becher R, Hoffmann B, Hoffken K, Schmidt CG (1984) Hormonal therapy and chemotherapy for male breast cancer. Verh Dtsch Krebs Ges 5: 619
Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas AT, Comaru-Schally AM, Schally AV (1982) Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA 79: 1658–1662
Treves N (1959) The treatment of cancer, especially inoperable cancer, of the male breast by ablative surgery (orchiectomy, adrenalectomy, and hypophysectomy) and hormone therapy (estrogens and corticosteroids). An analysis of 42 patients. Cancer 12: 820–832
Vilchez-Martinez JA, Pedroza E, Arimura A, Schally AV (1979) Paradoxical effects of D-Trp6- luteinizing hormone-releasing hormone on the hypothalamic-pituitary-gonadal axis in immature female rats. Fertil Steril 31: 677–682
Vorobiof DA, Falkson G (1987) Nasally administered buserelin inducing complete remission of lung metastases in male breast cancer. Cancer 59: 688–689
Wenderoth UK, Jacobi GH (1983) Gonadotropin-releasing hormone analogues for palliation of carcinoma of the prostate. A new approach to the classical concept. World J Urol 1: 40–48
Williams MR, Walker KJ, Turkes A, Blarney RW, Nicholson RI (1986) The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53: 629–636
Zubrod CG, Schneiderman M, Frei III E, Brindley C, Gold GL, Shnider B, Oviedo R, Gorman J, Jones R, Jonsson U, Colsky J, Chalmers T, Ferguson B, Dederick M, Holland J, Selawry O, Regelson W, Lasagna L, Owens Jr. AH (1960) Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and Methylene thiophosphoramide. J Chron Dis 11: 7–21
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Niederle, N., Doberauer, C., Scheuten, M.E., Schmidt, C.G. (1988). Buserelin as a Single Agent or in Combination with the Antiandrogen Flutamide in the Treatment of Advanced Male Breast Cancer. In: Höffken, K. (eds) LH-RH Agonists in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73530-1_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-73530-1_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73532-5
Online ISBN: 978-3-642-73530-1
eBook Packages: Springer Book Archive